Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The primary aim of this study was to characterize vitamin D status in term and preterm infants with cholestasis and to determine whether serum 25OHD concentrations were associated with gestational age, etiology of cholestasis, and biochemical markers of cholestatic activity.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This prospective observational study with a concurrent control group was conducted at the Children’s Memorial Health Institute in Warsaw.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D Status and Response to Calcifediol Supplementation in Term and Preterm Infants with Cholestasis

Observational study · Nutrients · 2026

Original publication title

Vitamin D Status and Response to Calcifediol Supplementation in Term and Preterm Infants with Cholestasis

Katarzyna Chada-Borowiecka; Justyna Czech-Kowalska; Edyta Czekuć-Kryśkiewicz; Ewa Skorupa; Marek Wójcik; Małgorzata Jarończyk; Rafał Bartczuk; Anna Niezgoda; Dariusz Gruszfeld

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Background/Objectives: Infants with cholestasis are at risk of vitamin D status impairment; the role of prematurity remains unclear. The primary aim of this study was to characterize vitamin D status in term and preterm infants with cholestasis and to determine whether serum 25OHD concentrations were associated with gestational age, etiology of cholestasis, and biochemical markers of cholestatic activity. The secondary aim was to assess changes in serum 25OHD concentrations during calcifediol supplementation and to identify factors associated with follow-up 25OHD concentrations.

Methods: In this prospective observational study with a concurrent control group, infants with cholestasis and controls underwent assessment, including serum 25-hydroxyvitamin D (25OHD), at baseline and after calcifediol supplementation in cholestatic infants. Predictors of 25OHD were evaluated using multivariable models. Results: We included 127 infants: 70 with cholestasis (39 term, 31 preterm) and 57 controls (30 term, 27 preterm). Biliary atresia was diagnosed in 21 (30%) infants. Calcifediol was administered to 38 (54%) cholestatic infants: 18 (46%) term and 20 (64%) preterm at baseline.

The remaining 32 infants with cholestasis were receiving vitamin D3 supplementation. Following enrollment and review of the baseline 25OHD results, calcifediol treatment was continued or initiated in 66 of the 70 infants. Treatment was discontinued in four infants based on their high serum 25OHD concentrations. Baseline 25OHD was similar in cholestasis and controls (34.81 ± 21.33 vs. 31.55 ± 10.14 ng/mL; p = 0.261). However, vitamin D deficiency (<20 ng/mL) was more frequent in cholestatic infants than controls (22.8% vs. 5%; p < 0.05), and 25OHD concentrations > 50 ng/mL were also more frequent (18.6% vs. 3.5%; p < 0.05).

Among 13 infants with 25OHD concentrations > 50 ng/mL, 11 (84.6%) infants had received calcifediol; only three exceeded 100 ng/mL. Each 1 µg/kg increase in calcifediol dose was associated with 15.7% higher expected baseline 25OHD. At follow-up, preterm and term infants had comparable 25OHD (44.15 ± 20.36 vs. 45.73 ± 18.77 ng/mL; p = 0.737); nevertheless, <30 ng/mL persisted in 23%, while >50 ng/mL occurred in 40% of cholestatic infants. Baseline 25OHD concentration and cumulative calcifediol exposure were associated with follow-up 25OHD concentration.

Conclusions: Vitamin D status in cholestatic infants is highly variable. Cumulative exposure of calcifediol is associated with higher 25OHD concentrations, but heterogeneous responses require monitoring and individualized dose adjustment.

Authors’ abstract

Background/Objectives: Infants with cholestasis are at risk of vitamin D status impairment; the role of prematurity remains unclear. The primary aim of this study was to characterize vitamin D status in term and preterm infants with cholestasis and to determine whether serum 25OHD concentrations were associated with gestational age, etiology of cholestasis, and biochemical markers of cholestatic activity. The secondary aim was to assess changes in serum 25OHD concentrations during calcifediol supplementation and to identify factors associated with follow-up 25OHD concentrations.

Methods: In this prospective observational study with a concurrent control group, infants with cholestasis and controls underwent assessment, including serum 25-hydroxyvitamin D (25OHD), at baseline and after calcifediol supplementation in cholestatic infants. Predictors of 25OHD were evaluated using multivariable models. Results: We included 127 infants: 70 with cholestasis (39 term, 31 preterm) and 57 controls (30 term, 27 preterm). Biliary atresia was diagnosed in 21 (30%) infants. Calcifediol was administered to 38 (54%) cholestatic infants: 18 (46%) term and 20 (64%) preterm at baseline.

The remaining 32 infants with cholestasis were receiving vitamin D3 supplementation. Following enrollment and review of the baseline 25OHD results, calcifediol treatment was continued or initiated in 66 of the 70 infants. Treatment was discontinued in four infants based on their high serum 25OHD concentrations. Baseline 25OHD was similar in cholestasis and controls (34.81 ± 21.33 vs. 31.55 ± 10.14 ng/mL; p = 0.261). However, vitamin D deficiency (<20 ng/mL) was more frequent in cholestatic infants than controls (22.8% vs. 5%; p < 0.05), and 25OHD concentrations > 50 ng/mL were also more frequent (18.6% vs. 3.5%; p < 0.05).

Among 13 infants with 25OHD concentrations > 50 ng/mL, 11 (84.6%) infants had received calcifediol; only three exceeded 100 ng/mL. Each 1 µg/kg increase in calcifediol dose was associated with 15.7% higher expected baseline 25OHD. At follow-up, preterm and term infants had comparable 25OHD (44.15 ± 20.36 vs. 45.73 ± 18.77 ng/mL; p = 0.737); nevertheless, <30 ng/mL persisted in 23%, while >50 ng/mL occurred in 40% of cholestatic infants. Baseline 25OHD concentration and cumulative calcifediol exposure were associated with follow-up 25OHD concentration.

Conclusions: Vitamin D status in cholestatic infants is highly variable. Cumulative exposure of calcifediol is associated with higher 25OHD concentrations, but heterogeneous responses require monitoring and individualized dose adjustment.

Publication and source details

Original title: Vitamin D Status and Response to Calcifediol Supplementation in Term and Preterm Infants with Cholestasis

Katarzyna Chada-Borowiecka; Justyna Czech-Kowalska; Edyta Czekuć-Kryśkiewicz; Ewa Skorupa; Marek Wójcik; Małgorzata Jarończyk; Rafał Bartczuk; Anna Niezgoda; Dariusz Gruszfeld

Nutrients · 2026

* Correspondence: j.kowalska@ipczd.pl; Tel.: +48-22-815-77-70© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Children’s Memorial Health Institutehttps://ror.org/020atbp69 M49/20Medical Research Agency2023/ABM/02/00015-00This research was funded by Young Investigators Project in The Children’s Memorial Health Institute, Warsaw; grant number M49/20. The work of MJ and RB on this article was supported by the Pediatrics Regional Centre for Digital Medicine (PeRCMC) project, funded by the Medical Research Agency from the Polish state budget under grant agreement No. 2023/ABM/02/00015-00, dated 27 October 2023, awarded to the Children’s Memorial Health Institute.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-08T11:18:26+00:00

DOI: 10.3390/nu18182962 · PMC13610632